Tristan Whitmarsh
Overview
Explore the profile of Tristan Whitmarsh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whitmarsh T, Cope W, Carmona-Bozo J, Manavaki R, Sammut S, Woitek R, et al.
Breast Cancer Res
. 2025 Feb;
27(1):17.
PMID: 39905431
Background: Tumour vascular density assessed from CD-31 immunohistochemistry (IHC) images has previously been shown to have prognostic value in breast cancer. Current methods to measure vascular density, however, are time-consuming,...
2.
Yu B, Whitmarsh T, Riede P, McDonald S, Kaggie J, Cox T, et al.
Bone
. 2024 Jun;
186:117142.
PMID: 38834102
Gaucher disease is one of the most common lysosomal storage disorders. Osteonecrosis is a principal clinical manifestation of Gaucher disease and often leads to joint collapse and fractures. T1-weighted (T1w)...
3.
Watson S, Duc B, Kang Z, de Tonnac A, Eling N, Font L, et al.
Nat Commun
. 2024 Apr;
15(1):3226.
PMID: 38622132
The tumor microenvironment plays a crucial role in determining response to treatment. This involves a series of interconnected changes in the cellular landscape, spatial organization, and extracellular matrix composition. However,...
4.
Gonzalez-Solares E, Dariush A, Gonzalez-Fernandez C, Kupcu Yoldas A, Molaeinezhad A, Al Sad M, et al.
Biol Imaging
. 2024 Mar;
3:e11.
PMID: 38487685
With the aim of producing a 3D representation of tumors, imaging and molecular annotation of xenografts and tumors (IMAXT) uses a large variety of modalities in order to acquire tumor...
5.
Sano H, Whitmarsh T, Skingle L, Shimakura T, Yamamoto N, Compston J, et al.
J Bone Miner Res
. 2023 Aug;
38(11):1603-1611.
PMID: 37548352
Romosozumab treatment reduces the rate of hip fractures and increases hip bone density, increasing bone formation by inhibiting sclerostin protein. We studied the normal pattern of bone formation and osteocyte...
6.
Hasan Z, Ahmed I, Matin R, Homer V, Lear J, Ismail F, et al.
Br J Dermatol
. 2022 Jan;
187(3):324-337.
PMID: 34988975
Background: The risk of cutaneous squamous cell carcinoma (cSCC) is significantly increased in organ transplant recipients (OTRs). Clearance of actinic keratoses (AKs) is generally regarded as a surrogate biomarker for...
7.
Poole K, Treece G, Pearson R, Gee A, Bolognese M, Brown J, et al.
J Bone Miner Res
. 2021 Nov;
37(2):256-264.
PMID: 34738660
Romosozumab monoclonal antibody treatment works by binding sclerostin and causing rapid stimulation of bone formation while decreasing bone resorption. The location and local magnitude of vertebral bone accrual by romosozumab...
8.
9.
Whitmarsh T, Otake Y, Uemura K, Takao M, Sugano N, Sato Y
Sci Rep
. 2019 Jan;
9(1):305.
PMID: 30670734
Bone is in a continuous state of remodeling whereby old bone is absorbed and new bone is formed in its place. During this process, new formations reinforce the bone in...
10.
Whitmarsh T, Treece G, Gee A, Poole K
Int J Comput Assist Radiol Surg
. 2017 Feb;
12(12):2079-2086.
PMID: 28233167
Purpose: The aim of this study was to develop and evaluate a method for measuring the cortical bone thickness from computed tomography (CT) scans with metallic implants and to assess...